Gustavo Oderich, M.D., FACS

Picture

Gustavo Oderich, M.D., FACS

Addresses

Baylor Medicine at McNair Campus (Clinic)
: 7200 Cambridge Street
Houston, TX 77030
United States

Education

Fellowship at Cleveland Clinic Foundation: Cleveland, OH; Advanced Endovascular

Clinical Fellowship at Mayo Clinic College of Medicine and Science: Rochester, MN; Vascular Surgery

Residency at Mayo Clinic College of Medicine and Science: Rochester, MN; General Surgery (Categorical)

Research Fellowship at University of Utah: Salt Lake City, UT; Vascular Surgery

Residency at Universidade Federal do Rio Grande do Sul: Porto Alegre, Brazil; General Surgery

MD from Universidade Federal do Rio Grande do Sul: Porto Alegre, Brazil

Certifications

General Surgery: American Board of Surgery

Vascular Surgery: American Board of Surgery

Honors & Awards

Who’s Who in America: Marquis (2012-2025)

Professional Interests

Aortic arch aneurysms and dissections
Aortoiliac aneurysms
Thoracoabdominal aortic aneurysms and dissections
Endovascular aortic repair
Fenestrated and branched endovascular aortic repair
Onco-vascular procedures

Professional Statement

Dr. Gustavo Oderich focuses on the clinical evaluation, open surgical and endovascular treatment of aneurysms, dissections, trauma and aortic pathology involving any segment of the aorta, including the aortoiliac, juxtarenal, pararenal, complex abdominal, thoracoabdominal and aortic arch. Dr. Oderich has a broad and extensive experience in the spectrum of arterial and venous diseases affecting all vascular beds, including carotid, supra-aortic trunk, upper and lower extremity, abdominal and pelvic vessels.

Dr. Oderich is a world-renowned authority on innovative minimally invasive endovascular techniques to treat complex aortic aneurysms using fenestrated and branched stent-grafts. He pioneered several techniques of physician-modified endovascular grafts (PMEGs) that are currently utilized in many centers and was instrumental in the development, technical improvements and dissection of fenestrated and branched stent-grafts using multiple designs. Dr. Oderich serves as the Global Principal Investigator for the ongoing Cook Zenith Plus Pivotal Study and the upcoming Thoraco Plus Pivotal Study, and has participated as principal investigator and member of steering committee in numerous other aortic device trials. He served as Chair for the Society for Vascular Surgery Reporting Standards on endovascular repair of complex aneurysms involving the renal and mesenteric arteries, and is a member of the writing committee of clinical practice guidelines for management of aortic diseases from the American Heart Association, American Society for Vascular Surgery and the European Society for Vascular and Endovascular Surgery. Dr. Oderich has several firsts, including the “first-in-man” implant of the antegrade design of the WL Gore TAMBE stent-graft (Thoraco-Abdominal Multi-Branch Endoprosthesis), first in man implant of the Cook ZFEN Plus stent-graft and first in man total trans-femoral three vessel arch device using antegrade branches. Dr. Oderich extensive clinical experience includes thousands of patients treated by open surgical and endovascular techniques. He has performed over 5,000 open and endovascular aortic repairs, including >2,000 standard endovascular aortic repairs (EVARs), > 500 thoracic endovascular aortic repairs (TEVARS) and >900 fenestrated-branched, fenestrated and branched endovascular repairs (FB-EVAR, FEVAR, BEVAR), bringing over two decades of experience from the Mayo Clinic. He was mentored by pioneering surgeon Roy Greenberg at the Cleveland Clinic and continues to evolve on improvements in complex endovascular techniques as well as open surgical techniques. He is one of ten surgeons in the United States, and the only surgeon in Houston to have physician sponsored, Food Drug Administration (FDA) approved access to the entire pipeline of company manufactured Cook fenestrated and branched stent-grafts to treat aortic arch, thoracoabdominal and complex abdominal aortic aneurysms. He is also involved in many industry sponsored device trials and is the first to have implanted the newl approved antegrade WL Gore TAMBE (ThoracoAbdominal Multi-Branch Endoprosthesis) worldwide. Dr. Oderich has also a versatile open surgical and endovascular practice in other areas, including management of carotid, supra-aortic trunk, renal and mesenteric artery diseases. He is also involved in the multidisciplinary care of patients with connective tissue disorders including Marfan’s, Loeys-Dietz Syndrome and Vascular Ehlers Danlos Syndrome. Dr. Oderich served as immediate past chair of the Vascular and Endovascular Surgery at the Mayo Clinic in Rochester, Minnesota (2006-2020) and at The University of Texas Health Science Center in Houston (2020-2024). His clinical practice at the Mayo Clinic was extensive rapidly accumulating one of the world’s largest experiences in aortic disease, where he led and build an advanced endovascular aortic program over the last two decades. He has been a mentor to over 100 residents, fellows and post-graduate students and is one of the most influential aortic surgeons on the dissemination of advanced endovascular techniques. Most importantly, he is one of the unique surgeons capable of carrying the most complex endovascular and open surgical procedures.

As the past director of the Aortic Center at the Mayo Clinic and now at Baylor, Dr. Oderich spearheaded and developed extensive clinical experience and innovations in aortic stent-graft design, novel techniques, imaging and clinical data that support indications for use of minimally invasive endovascular approaches. One of the most impressive contributions by Dr. Oderich is the reporting of one of the largest single surgeon experiences with the use of fenestrated-branched endovascular repair of aortic aneurysms and dissections using such devices, with significant reduction in mortality and morbidity and one of the lowest (if not the lowest) operative mortalities worldwide. As comparison, Dr. Oderich mortality for endovascular repair of thoracoabdominal aortic aneurysms has been consistently in the range of 1-1.5%, which is remarkably lower than the expected 15% mortality for open surgical repair in national datasets or 7-15% in single center open surgical experiences.